Found: 14
Select item for more details and to access through your institution.
Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 805, doi. 10.1111/dom.12486
- By:
- Publication type:
- Article
Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 789, doi. 10.1111/dom.12488
- By:
- Publication type:
- Article
Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 809, doi. 10.1111/dom.12500
- By:
- Publication type:
- Article
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 751, doi. 10.1111/dom.12474
- By:
- Publication type:
- Article
Efficacy of a long-acting C-peptide analogue against peripheral neuropathy in streptozotocin-diabetic mice.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 781, doi. 10.1111/dom.12477
- By:
- Publication type:
- Article
Inhibiting or antagonizing glucagon: making progress in diabetes care.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 720, doi. 10.1111/dom.12480
- By:
- Publication type:
- Article
Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 800, doi. 10.1111/dom.12481
- By:
- Publication type:
- Article
Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine ( Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study)
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 734, doi. 10.1111/dom.12482
- By:
- Publication type:
- Article
Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 760, doi. 10.1111/dom.12483
- By:
- Publication type:
- Article
Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 771, doi. 10.1111/dom.12484
- By:
- Publication type:
- Article
Diabetes, Obesity and Metabolism.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. i, doi. 10.1111/dom.12371
- Publication type:
- Article
Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 742, doi. 10.1111/dom.12473
- By:
- Publication type:
- Article
Role of probiotics in reducing the risk of gestational diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 713, doi. 10.1111/dom.12475
- By:
- Publication type:
- Article
Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine ( Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study.
- Published in:
- Diabetes, Obesity & Metabolism, 2015, v. 17, n. 8, p. 726, doi. 10.1111/dom.12496
- By:
- Publication type:
- Article